Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Wuhan University · Zhongnan Hospital of Wuhan University · +5 more institutions
Abstract
Abstract Background No clinically proven effective antiviral strategy exists for the epidemic Coronavirus Disease 2019 (COVID-19). Methods We conducted a prospective, randomized, controlled, open-label multicenter trial involving adult patients with COVID-19. Patients were randomly assigned in a 1:1 ratio to receive conventional therapy plus Umifenovir (Arbidol) (200mg*3/day) or Favipiravir (1600mg*2/first day followed by 600mg*2/day) for 10 days. The primary outcome was clinical recovery rate of Day 7. Latency to relief for pyrexia and cough, the rate of auxiliary oxygen therapy (AOT) or noninvasive mechanical ventilation (NMV) were the secondary outcomes. Safety data were collected for 17 days. Results 240…
Citation impact
- FWCI
- —
- Percentile
- —
- References
- 13
Authors
14- CCChang Chen
Wuhan University, Zhongnan Hospital of Wuhan University
- YZYi Zhang
Peking University, Wuhan University, Zhongnan Hospital of Wuhan University, Center for Life Sciences, Euler Technology (China)
- JHJianying Huang
Wuhan University, Zhongnan Hospital of Wuhan University
- PYPing Yin
Huazhong University of Science and Technology
- ZCZhenshun Cheng
Wuhan University, Zhongnan Hospital of Wuhan University
Topics & keywords
- Favipiravir
- Medicine
- Adverse effect
- Clinical trial
- Randomized controlled trial
- Randomization
- Coronavirus disease 2019 (COVID-19)
- Dose
- Good health and well-being
Funding
- CMCapital Medical University
- HUHuazhong University of Science and Technology
- TUTongji University
- WUWuhan University
- WUWuhan University of Science and Technology
- SUShanghai University of Traditional Chinese Medicine
- LHLonghua Hospital Shanghai University of Traditional Chinese Medicine
- SAScience and Technology Department of Hubei Province
- NKNational Key Research and Development Program of ChinaAward: 2020YFC0844400